RxDoctor Payments Data

Hussam Shaker

Neurology · Grand Rapids, MINPI 1861807315

Payments from drug & device makers

$10,501in general payments, 2019–2025

Across 28 payments — averaging $375.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • DIXI Medical USA Corp$10K
  • UCB, Inc.$434
  • SK Life Science, Inc.$175
  • Neurelis, Inc.$125
  • Greenwich Biosciences, Inc.$76
  • Supernus Pharmaceuticals, Inc.$37
  • plus $49 from 2 others

What the payments were for

  • Travel & lodging$5,73055%
  • Food & beverage$4,77045%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
DIXI Medical USA Corp12$9,604
UCB, Inc.4$434
SK Life Science, Inc.2$175
Neurelis, Inc.1$125
Greenwich Biosciences, Inc.5$76
Supernus Pharmaceuticals, Inc.2$37
Aucta Pharmaceuticals, Inc.1$25
Eisai Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,501 in reported general payments places this provider in the 75th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$43,475
Medicare patients
181
Services billed
511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)38$103,200
BriviactBrivaracetam54$77,533
LamictalLamotrigine22$44,871
Lamictal XrLamotrigine24$36,724
KeppraLevetiracetam18$35,447
FycompaPerampanel21$28,171
Lamotrigine ErLamotrigine34$27,871
Lacosamide222$27,042
XcopriCenobamate23$26,203
NayzilamMidazolam31$19,101
Levetiracetam301$11,181
CarbatrolCarbamazepine16$6,956
Clobazam95$4,785
Lamotrigine175$3,854
Levetiracetam ErLevetiracetam31$3,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$434$96,63385 claims
Eisai Inc.Fycompa$24$28,17121 claims
SK Life Science, Inc.Xcopri$175$26,20323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 652 neurology providers in Michigan.

Other neurology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →